Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Bausch Health Companies Inc. (T:BHC)

Business Focus: Pharmaceuticals (NEC)

INK Edge Outlook

Mostly sunny as of March 01, 2024
For the latest outlook, get the company report
This company is also listed in the United States as BHC on the NYSE. Click here to get the live US quote and see if there are any SEC insider filings..

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for BHC within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 06, 2024 08:00 ET
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
LAVAL, QC / ACCESSWIRE / March 6, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced that it is supporting a Phase 2 investigator-initiated study (IIS) of RELISTOR® (methylnaltrexone bromide: MNTX) in patients with resectable head and neck squamous cell carcinoma. An IIS is a study that is proposed, developed, and conducted by a qualified sponsor external to Bausch Health/Salix who assumes full responsibility for the study.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.94
--
--
Price to Sales - TTM
0.43
3.85
3.46
Price to Book - most recent quarter
--
2.75
2.02
Price to Cash Flow per share - TTM
5.79
7.41
9.70
Price to Free Cash Flow per share - TTM
4.98
19.71
12.33
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 20241,984,216-124,699
Feb 29, 20242,108,915-926,247
Feb 15, 20243,035,162-97,415
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

See business summary

 

Twitter

Search (past week) for $BHC.CA

  • No tweets found